All Oncology News

HS-20093 demonstrated durable responses and disease control in relapsed/refractory osteosarcoma and STS in phase 2 ARTEMIS-002 trial data presented at ESMO 2025.

Rahul Banerjee, MD, FACP, discusses the ongoing investigations of mezigdomide and CELMoDs in multiple myeloma.

Lung cancer experts stress the importance of lung cancer screening and discuss ways that technological advances are transforming screening processes and outcomes.

Erica L. Mayer, MD, MPH, discusses updated data with CDK4/6 inhibitors and ongoing investigations of oral SERDs in HR-positive breast cancer.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses innovations in brain surgery and the importance of balancing oncological and functional outcomes.

A research team at Roswell Park has identified an immune-suppressing metabolic checkpoint in the tumor microenvironment, and a way to overcome it.

The FDA has granted fast track designation to gamgertamig for autoimmune hemolytic anemia and immune thrombocytopenia.

The FDA has given priority review to a new drug application for gedatolisib in hormone receptor–positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Legubicin significantly improved PFS vs doxorubicin in advanced soft tissue sarcoma, with reduced cardiotoxicity and consistent benefit across subgroups.

Guillermo Garcia-Manero, MD, discusses how updated VERONA trial data showed no OS benefit with venetoclax plus azacitidine vs azacitidine alone in MDS.

The FDA approval of perioperative enfortumab vedotin plus pembrolizumab reshapes curative-intent care for cisplatin-ineligible MIBC.

Melphalan/HDS produced antitumor activity in metastatic uveal melanoma, including a consistent ORR across key subgroups.

Experts discuss the latest advancements in early lung cancer screening, including biomarkers and technologies that enhance detection and patient outcomes.

Patients with pancreatic lesions have been treated with endoscopy-guided microwave therapy according to researchers at WVU Medicine.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

The EMA has validated a Type II variation application for trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive metastatic breast cancer.

Toripalimab and chidamide demonstrated particularly notable efficacy outcomes in well-differentiated liposarcoma and dedifferentiated liposarcoma.

Xiuning Le, MD, PhD, discusses the FDA approval of sevabertinib for pretreated, advanced, nonsquamous NSCLC with tumors harboring HER2 TKD mutations.

Ianalumab plus ibrutinib showed promising efficacy and uMRD rates with manageable safety in a phase 1b study of patients with CLL.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Lorenzo Falchi, MD, discusses the FDA approval of epcoritamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

Micvotabart pelidotin produced early activity in head and neck squamous cell carcinoma as monotherapy and in combination with pembrolizumab.

Guilherme Nader-Marta, MD, and Erica L. Mayer, MD, MPH, discusses innovative treatments for HR-positive, HER2-negative metastatic breast cancer.

Scott M. Haake, MD, PhD, discusses how RNAseq-defined clusters could guide treatment selection in metastatic ccRCC, based on data from the OPTIC trial.

Anamorelin plus chemotherapy was well tolerated and potentially associated with efficacy in metastatic urothelial carcinoma.

Treatment with nogapendekin alfa inbakicept plus BCG prolonged duration of complete response compared with BCG alone in patients with BCG-naive NMIBC.

Treatment with an allogeneic CD19-directed CAR natural killer–cell therapy led to an ongoing complete response at 15 months in Waldenstrom lymphoma.

Mayo Clinic’s Department of Radiation Oncology has developed an AI monitoring tool to support clinicians in monitoring for prostate cancer recurrence.

Elena Elimova, MD, discusses findings for zanidatamab chemotherapy with/without tislelizumab in advanced HER2-positive gastroesophageal adenocarcinoma.